건염 치료 시장 규모, 점유율, 동향 분석 리포트 : 치료별, 증상별, 지역별, 부문별 예측(2025-2030년)

Tendonitis Treatment Market Growth & Trends:

The global tendonitis treatment market size is expected to reach USD 281.8 billion by 2030, registering a CAGR of 3.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growing participation in physical and sporting activities, directly influences the rise in prevalence of sports-related injuries. In addition, the rising incidence of occupational injuries is anticipated to contribute to the development and growth of the industry over the forecast period. The growing global geriatric population is susceptible to bone disorders, diabetes, arthritis, osteoarthritis, osteoporosis, or tendonitis. Industry participants that are constantly innovating advanced therapies and technologies in managing tendonitis are also contributing to the market growth.

Growing investments, industry collaborations, and increasing favorable government support are other key factors accelerating market growth. Over the past years, there has been a transition from proactive to preventive therapies in managing the health of sportspersons in preventing injuries. According to Standard Children's Health, in 2018, approximately 3.5 million out of 30 million adolescents participating in sporting activities in the U.S. incur sports-related injuries. As per studies, annually, around 775,000 adolescents receive therapies and treatments for sports-related injuries in the U.S. Major players are expanding their business footprint in both developed and emerging economies through product innovation and strengthening their distribution cycles.

During the COVID-19 pandemic and enforced lockdowns and travel restrictions imposed across countries, the industry growth was negatively impacted owing to a decline in the number of tendonitis treatment procedures. Postponement and cancellation of sporting events led to a decline in the incidence of sports-related injuries, thereby, resulting in a decline in the business performance of the market. In 2021, the therapy segment accounted for the largest share and is anticipated to grow significantly over the forecast period. This is owing to the high preference for non-invasive treatment procedures. The first line of treatment management is physical therapy, which is expected to witness considerable growth.

The Achilles tendonitis segment dominated the industry in 2022. This growth can be attributed to the growing incidence of sports-related injuries in sports players. As per studies, the incidence rate of Achilles tendonitis ranges between 5 to 10 individuals per 100,000 people. North America accounted for the largest share in 2022 owing to the presence of renowned manufacturers and distributors, growing incidence of sports-related & trauma injuries, and rising awareness about the availability of various therapies & surgical procedures.

Tendonitis Treatment Market Report Highlights:

• By treatment, the therapy segment dominated the tendonitis treatment industry with the largest revenue share in 2024. The increasing preference of patients with tendonitis for non-invasive treatments contributes to segment growth.
• By condition, the Achilles tendonitis segment dominated the market with a revenue share of 48.8% in 2024. The segment dominated the market due to the high incidence of Achilles tendonitis condition, particularly among athletes and individuals engaged in repetitive physical activities.
• North America tendonitis treatment market dominated with a revenue share of 42.2% in 2024. A growing number of surgeries performed for tendonitis in the region and increasing consumer disposable income levels are among the few factors that contribute to the region's growth.
• The Asia Pacific region is expected to witness the fastest growth in the tendonitis treatment market over the forecast period, driven by a combination of factors such as a large and rapidly aging population, increased awareness about musculoskeletal health, and rising healthcare investments.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Segment scope
  • 1.1.2. Regional scope
  • 1.1.3. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. Research Assumptions
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Condition outlook
  • 2.2.2. Treatment outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Tendonitis Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Regulatory Framework
• 3.4. Tendonitis Treatment: Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
  • 3.4.2. PESTLE Analysis

Chapter 4. Tendonitis Treatment Market Segment Analysis, By Treatment, 2018 - 2030 (USD Million)

• 4.1. Definition and Scope
• 4.2. Treatment Market Share Analysis, 2024 & 2030
• 4.3. Segment Dashboard
• 4.4. Global Tendonitis Treatment Market, by Treatment, 2018 to 2030
• 4.5. Therapy
  • 4.5.1. Therapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5.2. Hot and Cold Therapy
    • 4.5.2.1. Hot and Cold Therapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5.3. Physical Therapy
    • 4.5.3.1. Physical therapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5.4. Shockwave Therapy
    • 4.5.4.1. Shockwave Therapy market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.6. Surgery
  • 4.6.1. Surgery market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Tendonitis Treatment Market Segment Analysis, By Condition, 2018 - 2030 (USD Million)

• 5.1. Definition and Scope
• 5.2. Condition Market Share Analysis, 2024 & 2030
• 5.3. Segment Dashboard
• 5.4. Global Tendonitis Treatment Market, by Condition, 2018 to 2030
• 5.5. Tennis elbow
  • 5.5.1. Tennis elbow market estimates and forecasts, 2018 to 2030 (USD million)
• 5.6. Golfer's elbow
  • 5.6.1. Golfer's elbow market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.7. Pitcher's elbow
  • 5.7.1. Pitcher's elbow market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.8. Jumper's Knee
  • 5.8.1. Jumper's Knee market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.9. Swimmer's shoulder
  • 5.9.1. Swimmer's shoulder market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.10. Achilles Tendonitis
  • 5.10.1. Achilles tendonitis market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Tendonitis Treatment Market Segment Analysis, By Region, 2018- 2030 (USD Million)

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Regional Market Snapshot
• 6.4. Tendonitis Treatment Market Share by Region, 2024 & 2030:
• 6.5. North America
  • 6.5.1. North America tendonitis treatment market, 2018 - 2030 (USD Million)
  • 6.5.2. U.S.
    • 6.5.2.1. U.S. tendonitis treatment market, 2018 - 2030 (USD Million)
  • 6.5.3. Canada
    • 6.5.3.1. Canada tendonitis treatment market, 2018 - 2030 (USD Million)
  • 6.5.4. Mexico
    • 6.5.4.1. Mexico tendonitis treatment market, 2018 - 2030 (USD Million)
• 6.6. Europe
  • 6.6.1. Europe tendonitis treatment market, 2018 - 2030 (USD Million)
  • 6.6.2. UK
    • 6.6.2.1. UK tendonitis treatment market, 2018 - 2030 (USD Million)
  • 6.6.3. Germany
    • 6.6.3.1. Germany tendonitis treatment market, 2018 - 2030 (USD Million)
  • 6.6.4. France
    • 6.6.4.1. France tendonitis treatment market, 2018 - 2030 (USD Million)
  • 6.6.5. Italy
    • 6.6.5.1. Italy tendonitis treatment market, 2018 - 2030 (USD Million)
  • 6.6.6. Spain
    • 6.6.6.1. Spain tendonitis treatment market, 2018 - 2030 (USD Million)
  • 6.6.7. Norway
    • 6.6.7.1. Norway tendonitis treatment market, 2018 - 2030 (USD Million)
  • 6.6.8. Sweden
    • 6.6.8.1. Sweden tendonitis treatment market, 2018 - 2030 (USD Million)
  • 6.6.9. Denmark
    • 6.6.9.1. Denmark tendonitis treatment market, 2018 - 2030 (USD Million)
• 6.7. Asia Pacific
  • 6.7.1. Japan
    • 6.7.1.1. Japan tendonitis treatment market, 2018 - 2030 (USD Million)
  • 6.7.2. China
    • 6.7.2.1. China tendonitis treatment market, 2018 - 2030 (USD Million)
  • 6.7.3. India
    • 6.7.3.1. India tendonitis treatment market, 2018 - 2030 (USD Million)
  • 6.7.4. Australia
    • 6.7.4.1. Australia tendonitis treatment market, 2018 - 2030 (USD Million)
  • 6.7.5. South Korea
    • 6.7.5.1. South Korea tendonitis treatment market, 2018 - 2030 (USD Million)
  • 6.7.6. Thailand
    • 6.7.6.1. Thailand tendonitis treatment market, 2018 - 2030 (USD Million)
• 6.8. Latin America
  • 6.8.1. Brazil
    • 6.8.1.1. Brazil tendonitis treatment market, 2018 - 2030 (USD Million)
  • 6.8.2. Argentina
    • 6.8.2.1. Argentina tendonitis treatment market, 2018 - 2030 (USD Million)
• 6.9. MEA
  • 6.9.1. South Africa
    • 6.9.1.1. South Africa tendonitis treatment market, 2018 - 2030 (USD Million)
  • 6.9.2. Saudi Arabia
    • 6.9.2.1. Saudi Arabia tendonitis treatment market, 2018 - 2030 (USD Million)
  • 6.9.3. UAE
    • 6.9.3.1. UAE tendonitis treatment market, 2018 - 2030 (USD Million)
  • 6.9.4. Kuwait
    • 6.9.4.1. Kuwait tendonitis treatment market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company Categorization
• 7.3. Company Profiles
  • 7.3.1. Merck and Co., Inc.
    • 7.3.1.1. Company overview
    • 7.3.1.2. Financial performance
    • 7.3.1.3. Product benchmarking
    • 7.3.1.4. Strategic initiatives
  • 7.3.2. Bayer AG
    • 7.3.2.1. Company overview
    • 7.3.2.2. Financial performance
    • 7.3.2.3. Product benchmarking
    • 7.3.2.4. Strategic initiatives
  • 7.3.3. AstraZeneca
    • 7.3.3.1. Company overview
    • 7.3.3.2. Financial performance
    • 7.3.3.3. Product benchmarking
    • 7.3.3.4. Strategic initiatives
  • 7.3.4. Boehringer Ingelheim Pharmaceuticals, Inc.
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Abbott
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Pfizer
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. GlaxoSmithKline PLC
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Almatica Pharma, Inc.
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Teva Pharmaceuticals Industries
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives